Close Menu

NEW YORK (GenomeWeb) –Pharma firm Dalcor remains optimistic regarding its work to salvage the cardiology drug dalcetrapib and see it approved by the US Food and Drug Administration for a biomarker-specific patient population, despite negative results presented by a competitor earlier this week.  

The company's approach to the drug, a cholesterylester transfer protein (CETP) inhibitor, follows a precision medicine model that has become common in oncology but would be a milestone for the cardiology drug space.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.

A new analysis finds some cancers receive more nonprofit dollars than others.

An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.

In Science this week: comparative analysis of sex differences in mammal gene expression, and more.